Possibilities of IFN-free therapy of hepatitis C

Czech version

Authors: Petr Husa
Authors‘ workplace: Klinika infekčních chorob Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Petr Husa, CSc.
Published in: Vnitř Lék 2015; 61(Suppl 4): 24-29
Category: Reviews

Overview

Chronic hepatitis C therapy using Directly Acting Antivirals (DAA) has high efficacy (till 100 %), minimum contra-indications and extraordinarily favorable safety profile. Primarily, it is necessary to pay attention to drug-drug interactions. However they are well documented and successfully resolvable already in general clinical practice. Current possibilities of interferon-free therapy represent combinations of sofosbuvir with other DAA or with ribavirin and combination of paritaprevir boosted by ritonavir + ombitasvir ± dasabuvir (3D combination).

Key words:
chronic hepatitis C – paritaprevir – ombitasvir – dasabuvir – ribavirin

Sources

1. European Association for the Study of Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014; 60(2): 392–420. Erratum in: J Hepatol 2014; 61(1): 183–184. Dostupné z DOI: <http://doi: 10.1016/j.jhep.2013.11.003>.

2. European Association for the Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63(1): 199–236. Dostupné z DOI: <http:// doi: 10.1016/j.jhep.2015.03.025>.

3. AASLD recommendation for testing, managing, and treating hepatitis C. Dostupné z WWW: <http://www.hcvguidelines.org>.

4. Harvoni: Souhrnu údajů o přípravku (SPC). Datum revize textu 06.2015. Dostupné z WWW: <http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/003850/WC500177995.pdf>.

5. Urbánek P, Husa P, Šperl J et al. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV). Dostupné z WWW: <http://www.ces-hep.cz/file/415/guidelines-hcv-2015-chs--sil.pdf>.

6. Feld JJ, Kowdley KV, Coakley E et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370(17): 1594–1603.

7. Ferenci P, Bernstein D, Lalezari J et al. ABT-450/rombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370(21): 1983–1992.

8. Wyles DL, Sulkowski MS, Eron JJ et al. TURQUOISE-I: 94% SVR12 in HCV/HIV-1 coinfected patients treated with ABT-450/r/ombitasvir, dasabuvir and ribavirin. Hepatology 2014; 60(Suppl 1): 1136A.

9. Zeuzem S, Jacobson IM, Baykal T et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370(17): 1604–1614.

10. Andreone P, Colombo MG, Enejosa JV et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147(2): 359–365.

11. Poordad F, Hezode C, Trinh R et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370(21): 1973–1982.

12. Pol S, Reddy KR, Baykal T et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results. Hepatology 2014; 60(Suppl 1): 1129A.

13. Urbánek P. Exviera, Viekirax. Gastroent Hepatol 2015; 69(1): 75–80.

14. University of Liverpool. Drug interactions charts. Dostupné z WWW: <http:// www.hep-druginteractions.com>.

Labels

Diabetology Endocrinology Internal medicine

Approach to patients with liver diseases

Cirrhosis of the liver and HCV

Article was published in

Internal Medicine

2015 Issue Suppl 4